Laekna, Inc. (HK:2105) has released an update.
Laekna, Inc. has announced the initiation of a phase I clinical trial for LAE102, a new monoclonal antibody therapy for obesity, with the first participant now dosed in China. The trial will assess the safety, tolerability, and pharmacokinetics of LAE102, aiming to offer a novel treatment that reduces fat and preserves muscle mass in overweight and obesity patients. Investors are cautioned, however, that LAE102’s development and commercialization are still uncertain and involve risks.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.
